Endologix Enters into an Agreement with Deerfield Partners to Take the Company Private
(WorldNews Europe)

PDF Version Commences voluntary Chapter 11 process with access to $30.8 million in DIP financing Files consensual plan of reorganization that would reduce approximately $180 million in debt and provide an approximately $30 million in additional exit financing Confirms launch of Alto this summer, steady production, continued clinical studies, and accelerated pipeline Expects to emerge well capitalized by the end of the third quarter of 2020, positioned for long-term growth IRVINE, Calif.--(BUSINESS WIRE)--Jul. 5, 2020-- Endologix, Inc. (Nasdaq: ELGX) (`Endologix` or `the Company`), a developer and marketer of innovative treatments for aortic disorders, today announced that, after evaluating a...